Interchangeable biosimilars to Prolia and Xgeva target osteoporosis and cancer-related bone complications in a $5 billion U.S. market
The center combines rigorous scientific instruction with practical, hands-on training, equipping providers with the clinical, consultative, and business skills needed to deliver safe, effective, and patient-centered care
The financing includes a four-year interest-only period, extendable to five years if a net sales milestone is achieved
Immediate U.S. launch planned for Farxiga®-equivalent diabetes drug; opportunity pegged at $10.2 billion in annual market size
Immediate U.S. launch planned for dapagliflozin-metformin ER tablets; addressable market estimated at $514 millionannually
New filtration lines will boost global drug supply and strengthen India’s role in Merck’s manufacturing network
Sharp increase in diabetes, hypertension and fatty liver in 30–50 age group
India’s first prospective study finds molecular testing improved diagnostic clarity in 50% of complex sarcoma cases
Health of the Nation 2026, based on over 3 million assessments, finds rising diabetes, obesity, and hidden cardiac risks in under-30s and working professionals
Subscribe To Our Newsletter & Stay Updated